Overview

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Status:
Not yet recruiting

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Servier Bio-Innovation LLC

Collaborators:

Institut de Recherches Internationales Servier
Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab